Advanced search
Publication Cover
Cancer Investigation Volume 33, 2015 - Issue 4
Submit an article Journal homepage
143
Views
8
CrossRef citations to date
0
Altmetric
ORIGINAL ARTICLES

Could Concomitant Radio-Chemotherapy Improve the Outcomes of Early-Stage Node Negative Anal Canal Cancer Patients? A Retrospective Analysis of 122 Patients

Berardino De BariRadiotherapy Department, Istituto del Radio di Brescia, University of Brescia, Brescia, Italy;Radiotherapy Department, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanna, Switzerland,Correspondence[email protected]
,
Laëtitia LestradeRadiation Oncology Department, Anticancer Center “Centre Léon Bérard”, Lyon, France,;Radiotherapy Department, Hopitaux Universitaires de Genève (HUG), Genève, Switzerland
,
Pascal PommierRadiation Oncology Department, Anticancer Center “Centre Léon Bérard”, Lyon, France,
,
Marta MaddaloRadiotherapy Department, Istituto del Radio di Brescia, University of Brescia, Brescia, Italy
,
Michela BuglioneRadiotherapy Department, Istituto del Radio di Brescia, University of Brescia, Brescia, Italy
,
Stefano Maria MagriniRadiotherapy Department, Istituto del Radio di Brescia, University of Brescia, Brescia, Italy
&
 Christian CarrieRadiation Oncology Department, Anticancer Center “Centre Léon Bérard”, Lyon, France,
 show all
Pages 114-120 | Received 28 Jul 2014, Accepted 15 Dec 2014, Published online: 12 Feb 2015
 
Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days

Abstract

One hundred twenty-two early-stage anal canal cancer patients (median age: 69 years) were treated with curative radiotherapy with (70 patients) or without (52 patients) concomitant chemotherapy. Median follow-up was 65 months (range: 4–238). At multivariate analysis, concomitant chemotherapy significantly improved local control (p = .007). Local control significantly influenced all considered endpoints, except the metastases free survival. The global rates of G3–G4 acute and late toxicity were 13.1% and 8.2%, respectively, and they were not increased by concomitant chemotherapy. Finally, concomitant chemotherapy is efficacious and safe in the treatment of T1-2N0 anal canal cancer patients and should be prospectively studied.

Log in via your institution

Access through your institution

Log in to Taylor & Francis Online

Restore content access

Restore content access for purchases made as guest
Purchase options * Save for later

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 65.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 1,193.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.